appliedclinicaltrialsonline1h
Updated TALAPRO-2 Trial Data Confirms Talzenna Plus Xtandi Significantly Improves Survival in Metastatic Castration-Resistant Prostate Cancer
Updated data from the Phase III TALAPRO-2 trial show that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly improves overall survival in patients with metastatic ...
appliedclinicaltrialsonline19h
Clinical Research, DEI Initiatives Caught in Political Headwinds Amidst Funding Freeze
Recent actions by the FDA and NIH in response to the current political climate have left key stakeholders in clinical trials ...
appliedclinicaltrialsonline21h
Lightship’s Approach to Accessible, Inclusive, and Impactful Clinical Trials
Sepehr Shojaei, VP of Design Solutions at Lightship, talks about how the company works with pharma and contract research ...